JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

Search

Boston Scientific Corp.

Gesloten

SectorGezondheidszorg

76.24 -1.8

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

75.38

Max

76.86

Belangrijke statistieken

By Trading Economics

Inkomsten

-40M

755M

Verkoop

4M

5.1B

K/W

Sectorgemiddelde

49.128

84.243

EPS

0.75

Winstmarge

14.906

Werknemers

53,000

EBITDA

1M

1.4B

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+41.79% upside

Dividenden

By Dow Jones

Volgende Winsten

22 apr 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-13B

136B

Vorige openingsprijs

78.04

Vorige sluitingsprijs

76.24

Nieuwssentiment

By Acuity

35%

65%

92 / 352 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Boston Scientific Corp. Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 feb 2026, 16:14 UTC

Winsten
Belangrijke Marktbewegers

Boston Scientific Plunges on Disappointing 1Q Outlook Despite 4Q Earnings Beat

4 feb 2026, 12:13 UTC

Winsten

Boston Scientific Sees More Growth after Earnings, Sales Rise

15 jan 2026, 13:29 UTC

Acquisities, Fusies, Overnames

Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock -- 2nd Update

15 jan 2026, 12:35 UTC

Acquisities, Fusies, Overnames

Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock -- Update

15 jan 2026, 12:29 UTC

Acquisities, Fusies, Overnames

Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock

4 feb 2026, 21:41 UTC

Winsten

These Stocks Are Today's Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More -- Barrons.com

4 feb 2026, 19:38 UTC

Winsten

These Stocks Are Today's Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More -- Barrons.com

4 feb 2026, 17:32 UTC

Winsten

These Stocks Are Today's Movers: AMD, AbbVie, Eli Lilly, Boston Scientific, MP Materials, Super Micro, Silicon Labs, Uber, and More -- Barrons.com

4 feb 2026, 15:30 UTC

Winsten

Boston Scientific Earnings Beat Estimates. It's the Worst Stock in the S&P 500 Today. -- Barrons.com

4 feb 2026, 15:29 UTC

Winsten

These Stocks Are Today's Movers: AMD, Eli Lilly, AbbVie, Uber, Super Micro, Enphase, Boston Scientific, and More -- Barrons.com

4 feb 2026, 14:06 UTC

Winsten

Boston Scientific Profit, Sales Rise but Issues Soft Guidance -- Update

4 feb 2026, 13:58 UTC

Winsten

Boston Scientific Earnings Beat Expectations. Why the Stock Is Down Sharply. -- Barrons.com

4 feb 2026, 13:12 UTC

Winsten

Boston Scientific Earnings Beat Expectations. Why the Stock Is Down Sharply. -- Barrons.com

4 feb 2026, 11:32 UTC

Winsten

Boston Scientific Sees 2026 Sales Up 10.5%-11.5%, Organic Sales Up 10%-11% >BSX

4 feb 2026, 11:31 UTC

Winsten

Boston Scientific Sees 1Q Sales Up 10.5%-12%, Organic Sales Up 8.5%-10% >BSX

4 feb 2026, 11:30 UTC

Winsten

Boston Scientific 4Q Organic Sales Up 12.7% >BSX

4 feb 2026, 11:30 UTC

Winsten

Boston Scientific Sees 2026 Adj EPS $3.43-Adj EPS $3.49 >BSX

4 feb 2026, 11:30 UTC

Winsten

Boston Scientific Sees 1Q Adj EPS 78c-Adj EPS 80c >BSX

4 feb 2026, 11:30 UTC

Winsten

Boston Scientific 4Q Adj EPS 80c >BSX

4 feb 2026, 11:30 UTC

Winsten

Boston Scientific 4Q Sales $5.29B >BSX

4 feb 2026, 11:30 UTC

Winsten

Boston Scientific 4Q EPS 45c >BSX

24 jan 2026, 06:18 UTC

Acquisities, Fusies, Overnames

Our Boston Scientific Pick Has Stumbled. Acquiring Penumbra Will Help the Stock. -- Barrons.com

15 jan 2026, 14:37 UTC

Populaire aandelen

Stocks to Watch Thursday: Goldman Sachs, Boston Scientific, BlackRock -- WSJ

15 jan 2026, 13:45 UTC

Acquisities, Fusies, Overnames

Penumbra Stock Jumps. It's Being Bought by Boston Scientific for $14.5 Billion. -- Barrons.com

15 jan 2026, 12:04 UTC

Acquisities, Fusies, Overnames

Boston Scientific: Penumbra Shareholders Can Elect to Receive Cash or Stock >BSX PEN

15 jan 2026, 12:03 UTC

Acquisities, Fusies, Overnames

Boston Scientific: Acquisition to Expand Cardiovascular Portfolio >BSX PEN

15 jan 2026, 12:01 UTC

Acquisities, Fusies, Overnames

Boston Scientific: Penumbra Deal Carriers an Enterprise Value of About $14.5 Billion >BSX

15 jan 2026, 12:00 UTC

Acquisities, Fusies, Overnames

Boston Scientific to Buy Penumbra for $374/Share >BSX PEN

15 jan 2026, 12:00 UTC

Acquisities, Fusies, Overnames

Boston Scientific Announces Agreement To Acquire Penumbra, Inc. >BSX PEN

12 jan 2026, 12:04 UTC

Acquisities, Fusies, Overnames

Boston Scientific Sees Immaterial Impact to 2026 Adjusted EPS >BSX

Peer Vergelijking

Prijswijziging

Boston Scientific Corp. Prognose

Koersdoel

By TipRanks

41.79% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 108.14 USD  41.79%

Hoogste 132 USD

Laagste 94 USD

Gebaseerd op 22 Wall Street-analisten die 12-maands prijsdoelen bieden voor Boston Scientific Corp. - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

22 ratings

22

Buy

0

Hold

0

Sell

Technische score

By Trading Central

102.95 / 104.93Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Weak Bearish Evidence

Lange Termijn

No Evidence

Sentiment

By Acuity

92 / 352 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Boston Scientific Corp.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
help-icon Live chat